Mesoblast Stock News

The Mesoblast share price is in the green today as investors respond positively to the company''s latest update. The post Mesoblast (ASX:MSB) share price crawls higher on Q1 trading update appeared first on The Motley Fool Australia .

Drugmaker Mesoblast (ASX:MSB) is trading slightly higher on the ASX today following the release of its financial results for the three months to the end of September 2021.

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the first quarter ended September 30, 2021.

Mesoblast Limited (NASDAQ:MESO)s stock price traded up 9.9% during trading on Tuesday . The company traded as high as $6.91 and last traded at $6.87. 14,126 shares were traded during mid-day trading, a decline of 95% from the average session volume of 297,577 shares. The stock had previously closed at $6.25. A number of equities []

NEW YORK, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operation

Mesoblast Limited (NASDAQ: MESO ) refinanced its existing senior debt facility with a new $90 million five-year facility provided by Oaktree Capital Management LP . Mesoblast drew the first tranche of $60 million on closing, with proceeds being used to repay the outstanding balance of the existing senior debt facility with Hercules Capital Inc . An additional $30 million may be drawn by December Full story available on Benzinga.com

Mesoblast Limited (NASDAQ: MESO) refinanced its existing senior debt facility with a new $90 million five-year facility provided by Oaktree Capital Management LP. Mesoblast drew the first tranche

22 Nov 2021 - A snapshot of the stocks on the move, featuring Meridian Energy (ASX:MEZ), AMP (ASXAMP), Mesoblast (ASX:MSB).

NEW YORK, Nov. 21, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has successfully refinanced its existing senior debt facility with a new US$90 million five year facility provided by funds managed by Oaktree Capital Management, L.P. (Oaktree).

What''s happened to the company''s shares? The post Mesoblast (ASX:MSB) share price tumbles 8% giving back most of yesterdays gains appeared first on The Motley Fool Australia .

These ASX shares are out of form The post Why Best & Less, BHP, Mesoblast, and Nearmap shares are falling appeared first on The Motley Fool Australia .

The ASX’s big biotechs, particular Mesoblast (ASX:MSB), have had intriguing years in 2021, but there could be more to look … Read More The post Mesoblast and the ASX’s other big biotechs have intrigued investors this year; here’s what’s in store next appeared first on Stockhead .

Mesoblast (NASDAQ:MESO) and Advanced Life Sciences (OTCMKTS:ADLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation. Analyst Ratings This is a breakdown of current recommendations and price targets for Mesoblast and Advanced []